Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Philip J. Mease, Stephen Hall, Oliver FitzGerald, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 16, pp. 1537-1550
Open Access | Times Cited: 511

Showing 1-25 of 511 citing articles:

The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1487
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna D. Gladman, William F. C. Rigby, Valdeŕilio Feijó Azevedo, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 16, pp. 1525-1536
Open Access | Times Cited: 470
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Yoshiya Tanaka, Yiming Luo, John J. O’Shea, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 3, pp. 133-145
Open Access | Times Cited: 334
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease, Proton Rahman, Alice B. Gottlieb, et al.
The Lancet (2020) Vol. 395, Iss. 10230, pp. 1126-1136
Open Access | Times Cited: 278
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
G. Fragoulis, Iain B. McInnes, Stefan Siebert
Lara D. Veeken (2018) Vol. 58, Iss. Supplement_1, pp. i43-i54
Open Access | Times Cited: 270
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease, Josef S Smolen, Frank Behrens, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 123-131
Open Access | Times Cited: 249
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Yvan Jamilloux, Thomas El Jammal, Lucine Vuitton, et al.
Autoimmunity Reviews (2019) Vol. 18, Iss. 11, pp. 102390-102390
Closed Access | Times Cited: 233
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 226
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 205
Psoriasis: A STAT3-Centric View
Enzo Calautti, Lidia Avalle, Valeria Poli
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 1, pp. 171-171
Open Access | Times Cited: 203
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease, Apinya Lertratanakul, J. Anderson, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 312-320
Open Access | Times Cited: 199
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Atul Deodhar, Paula Śliwińska-Stańczyk, Huji Xu, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 8, pp. 1004-1013
Open Access | Times Cited: 195
Psoriatic arthritis
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 194
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He, Emma Guttman‐Yassky
American Journal of Clinical Dermatology (2018) Vol. 20, Iss. 2, pp. 181-192
Closed Access | Times Cited: 193
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip J. Mease, Laura C. Coates, Philip Helliwell, et al.
The Lancet (2018) Vol. 392, Iss. 10162, pp. 2367-2377
Open Access | Times Cited: 188
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
Marie‐Astrid Boutet, Alessandra Nerviani, Gabriele Gallo Afflitto, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 530-530
Open Access | Times Cited: 182
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Sara G. Manore, Daniel Doheny, Grace L. Wong, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 171
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 778-786
Open Access | Times Cited: 169
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 167
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi Fei, Fang Liu, Ling Gao
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 122
Psoriatic arthritis from a mechanistic perspective
Georg Schett, Proton Rahman, Christopher T. Ritchlin, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 6, pp. 311-325
Closed Access | Times Cited: 94
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 76
Page 1 - Next Page

Scroll to top